English

Adamas Pharmaceuticals Inc

EDGAR

ADMS Quarterly report (10-Q) · filed 2021-11-10

150 filing records in this dataset, filed from 2014-03-05 to 2021-11-10. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

25.9 million USD

2021 Q3 · USD

Exact inputs and evidence

Revenue: 25896000 USD Source

Operating margin

-21.76%

2021 Q3 · %

Exact inputs and evidence

Operating Income: -5636000 USD Source
Revenue: 25896000 USD Source

Operating cash flow

-6.25 million USD

2021 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -36486000 USD Source
Operating Cash Flow: -30241000 USD Source

Free cash flow

-6.25 million USD

2021 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -36486000 USD Source
Operating Cash Flow: -30241000 USD Source
Capital Expenditure: 38000 USD Source
Capital Expenditure: 30000 USD Source

Cash and cash equivalents: 78.6 million USD 2021-09-30 Source
Exact value

78623000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 45.7 million shares 2021-09-30 Source
Exact value

45690547 shares

Reported share-count change

60.20% · 17.2 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

28520519 shares · 2020-09-30· Source
45690547 shares · 2021-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

88.2 million USD

2020-10-01 – 2021-09-30

Exact inputs and evidence

Revenue: 74461000 USD · 2020-01-01 – 2020-12-31 Source
Revenue: 53451000 USD · 2020-01-01 – 2020-09-30 Source
Revenue: 19311000 USD · 2021-01-01 – 2021-03-31 Source
Revenue: 21972000 USD · 2021-04-01 – 2021-06-30 Source
Revenue: 25896000 USD · 2021-07-01 – 2021-09-30 Source

Net income

-62.7 million USD

2020-10-01 – 2021-09-30

Exact inputs and evidence

Net income: -57403000 USD · 2020-01-01 – 2020-12-31 Source
Net income: -39130000 USD · 2020-01-01 – 2020-09-30 Source
Net income: -12573000 USD · 2021-01-01 – 2021-03-31 Source
Net income: -12344000 USD · 2021-04-01 – 2021-06-30 Source
Net income: -19518000 USD · 2021-07-01 – 2021-09-30 Source

Operating cash flow

-46.8 million USD

2020-10-01 – 2021-09-30

Exact inputs and evidence

Operating cash flow: -50708000 USD · 2020-01-01 – 2020-12-31 Source
Operating cash flow: -40381000 USD · 2020-01-01 – 2020-09-30 Source
Operating cash flow: -21063000 USD · 2021-01-01 – 2021-03-31 Source
Operating cash flow: -30241000 USD · 2021-01-01 – 2021-06-30 Source
Operating cash flow: -21063000 USD · 2021-01-01 – 2021-03-31 Source
Operating cash flow: -36486000 USD · 2021-01-01 – 2021-09-30 Source
Operating cash flow: -30241000 USD · 2021-01-01 – 2021-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2021-11-10.

Financial data available through: 2020-12-31.

Coverage by financial measure

Revenue: 7 of 11 periods available· newest 2020-12-31
Operating income: 7 of 11 periods available· newest 2020-12-31
Net income: 7 of 11 periods available· newest 2020-12-31
Operating cash flow: 7 of 11 periods available· newest 2020-12-31
Capital expenditure: 7 of 11 periods available· newest 2020-12-31
Total assets: 7 of 11 periods available· newest 2020-12-31
Total liabilities: 7 of 11 periods available· newest 2020-12-31
Current assets: 7 of 11 periods available· newest 2020-12-31
Current liabilities: 7 of 11 periods available· newest 2020-12-31
Cash and cash equivalents: 9 of 11 periods available· newest 2020-12-31
long term debt: No compatible figures in this window
Shares outstanding: 7 of 11 periods available· newest 2020-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+36.3%

Prior period

USD 54.64 million

2019-01-01 – 2019-12-31
Current period

USD 74.46 million

2020-01-01 – 2020-12-31

Exact inputs and evidence

74461000 − 54637000 = 19824000 USD

54637000 USD · 2019-01-01 – 2019-12-31
Inspect prior input Prior source
74461000 USD · 2020-01-01 – 2020-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Adamas Pharmaceuticals Inc · 2020-12-31 Adamas Pharmaceuticals Inc (edgar:1328143) Year-over-year change in Revenue: 19824000 USD Concept: fundies:Revenue Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1328143?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 74461000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000132814321000019/adms-20201231.htm#793780 Filing: 000132814321000019 Input fundies:Revenue: 54637000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000132814321000019/adms-20201231.htm#794827 Filing: 000132814321000019
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 47.78 million

Prior period

−USD 105.19 million

2019-01-01 – 2019-12-31
Current period

−USD 57.4 million

2020-01-01 – 2020-12-31

Exact inputs and evidence

-57403000 − -105186000 = 47783000 USD

-105186000 USD · 2019-01-01 – 2019-12-31
Inspect prior input Prior source
-57403000 USD · 2020-01-01 – 2020-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Adamas Pharmaceuticals Inc · 2020-12-31 Adamas Pharmaceuticals Inc (edgar:1328143) Year-over-year change in Net income: 47783000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1328143?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -57403000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000132814321000019/adms-20201231.htm#1773928 Filing: 000132814321000019 Input fundies:NetIncome: -105186000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000132814321000019/adms-20201231.htm#1775175 Filing: 000132814321000019
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 30.07 million

Prior period

−USD 80.78 million

2019-01-01 – 2019-12-31
Current period

−USD 50.71 million

2020-01-01 – 2020-12-31

Exact inputs and evidence

-50708000 − -80779000 = 30071000 USD

-80779000 USD · 2019-01-01 – 2019-12-31
Inspect prior input Prior source
-50708000 USD · 2020-01-01 – 2020-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Adamas Pharmaceuticals Inc · 2020-12-31 Adamas Pharmaceuticals Inc (edgar:1328143) Year-over-year change in Operating cash flow: 30071000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1328143?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -50708000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000132814321000019/adms-20201231.htm#981723 Filing: 000132814321000019 Input fundies:OperatingCashFlow: -80779000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000132814321000019/adms-20201231.htm#982773 Filing: 000132814321000019
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-100%

Prior period

USD 18,000

2019-01-01 – 2019-12-31
Current period

USD 0

2020-01-01 – 2020-12-31

Exact inputs and evidence

0 − 18000 = -18000 USD

18000 USD · 2019-01-01 – 2019-12-31
Inspect prior input Prior source
0 USD · 2020-01-01 – 2020-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Adamas Pharmaceuticals Inc · 2020-12-31 Adamas Pharmaceuticals Inc (edgar:1328143) Year-over-year change in Capital expenditure: -18000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1328143?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 0 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000132814321000019/adms-20201231.htm#985048 Filing: 000132814321000019 Input fundies:CapitalExpenditure: 18000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000132814321000019/adms-20201231.htm#986032 Filing: 000132814321000019
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2020 2020-01-01 – 2020-12-31

Revenue USD 74.46 million 100% of revenue
Cost of revenue USD 2.04 million 2.7% of revenue
Operating expenses USD 116.59 million 157% of revenue
Operating income −USD 44.16 million −59% of revenue
Tax, interest and other Derived USD 13.24 million 18% of revenue
Net income −USD 57.4 million −77% of revenue

Cash

Operating cash flow −USD 50.71 million −68% of revenue
Capital expenditure USD 0 0% of revenue
Free cash flow Derived −USD 50.71 million −68% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2014 18%15%67%
2015 Operating loss: operating costs were 3,098% of revenue.
2016 Operating loss: operating costs were 10,762% of revenue.
2017 Operating loss: operating costs were 15,499% of revenue.
2018 Operating loss: operating costs were 438% of revenue.
2019 Operating loss: operating costs were 269% of revenue.
2020 Operating loss: operating costs were 159% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2014 2014-01-01 – 2014-12-31	55846000	37332000 Derived	18514000	8291000 Derived	10223000	26508000 Derived	Source 2014-01-01 – 2014-12-31: 55846000 USD Inspect Revenue Open source 2014-01-01 – 2014-12-31: 18514000 USD Inspect Operating Income Open source 2014-01-01 – 2014-12-31: 10223000 USD Inspect Net Income Open source 2014-01-01 – 2014-12-31: 27793000 USD Inspect Operating Cash Flow Open source 2014-01-01 – 2014-12-31: 1285000 USD Inspect Capital Expenditure Open source
2015 2015-01-01 – 2015-12-31	1916000	59353000 Derived	-57437000	-5635000 Derived	-51802000	-48609000 Derived	Source 2015-01-01 – 2015-12-31: 1916000 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: -57437000 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: -51802000 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: -47210000 USD Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 1399000 USD Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	572000	61556000 Derived	-60984000	-926000 Derived	-60058000	-49692000 Derived	Source 2016-01-01 – 2016-12-31: 572000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -60984000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -60058000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -48068000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 1624000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	571000	88497000 Derived	-87926000	1564000 Derived	-89490000	-68085000 Derived	Source 2017-01-01 – 2017-12-31: 571000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -87926000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -89490000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -66827000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 1258000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	34046000	149068000 Derived	-115022000	15977000 Derived	-130999000	-105287000 Derived	Source 2018-01-01 – 2018-12-31: 34046000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -115022000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -130999000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -104223000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 1064000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	54637000	146872000 Derived	-92235000	12951000 Derived	-105186000	-80797000 Derived	Source 2019-01-01 – 2019-12-31: 54637000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -92235000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -105186000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -80779000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 18000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	74461000	118625000 Derived	-44164000	13239000 Derived	-57403000	-50708000 Derived	Source 2020-01-01 – 2020-12-31: 74461000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -44164000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -57403000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -50708000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 0 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 74.5M 2020

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20142014-12-31	Revenue	55846000	Revenue: 55846000 Open source
20152015-12-31	Revenue	1916000	Revenue: 1916000 Open source
20162016-12-31	Revenue	572000	Revenue: 572000 Open source
20172017-12-31	Revenue	571000	Revenue: 571000 Open source
20182018-12-31	Revenue	34046000	Revenue: 34046000 Open source
20192019-12-31	Revenue	54637000	Revenue: 54637000 Open source
20202020-12-31	Revenue	74461000	Revenue: 74461000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

36.3% 2020

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20142014-12-31	Year over year	No prior comparable period	Revenue: 55846000 Open source
20152015-12-31	Year over year	-96.6%	Revenue: 1916000 Open source Revenue: 55846000 Open source
20162016-12-31	Year over year	-70.1%	Revenue: 572000 Open source Revenue: 1916000 Open source
20172017-12-31	Year over year	-0.2%	Revenue: 571000 Open source Revenue: 572000 Open source
20182018-12-31	Year over year	5,862.5%	Revenue: 34046000 Open source Revenue: 571000 Open source
20192019-12-31	Year over year	60.5%	Revenue: 54637000 Open source Revenue: 34046000 Open source
20202020-12-31	Year over year	36.3%	Revenue: 74461000 Open source Revenue: 54637000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -59.3% 2020

Net margin -77.1% 2020

Free cash flow margin -68.1% 2020

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20142014-12-31	Operating margin	33.2%	Operating Income: 18514000 Open source Revenue: 55846000 Open source
20152015-12-31	Operating margin	-2,997.8%	Operating Income: -57437000 Open source Revenue: 1916000 Open source
20162016-12-31	Operating margin	-10,661.5%	Operating Income: -60984000 Open source Revenue: 572000 Open source
20172017-12-31	Operating margin	-15,398.6%	Operating Income: -87926000 Open source Revenue: 571000 Open source
20182018-12-31	Operating margin	-337.8%	Operating Income: -115022000 Open source Revenue: 34046000 Open source
20192019-12-31	Operating margin	-168.8%	Operating Income: -92235000 Open source Revenue: 54637000 Open source
20202020-12-31	Operating margin	-59.3%	Operating Income: -44164000 Open source Revenue: 74461000 Open source
20142014-12-31	Net margin	18.3%	Net Income: 10223000 Open source Revenue: 55846000 Open source
20152015-12-31	Net margin	-2,703.7%	Net Income: -51802000 Open source Revenue: 1916000 Open source
20162016-12-31	Net margin	-10,499.7%	Net Income: -60058000 Open source Revenue: 572000 Open source
20172017-12-31	Net margin	-15,672.5%	Net Income: -89490000 Open source Revenue: 571000 Open source
20182018-12-31	Net margin	-384.8%	Net Income: -130999000 Open source Revenue: 34046000 Open source
20192019-12-31	Net margin	-192.5%	Net Income: -105186000 Open source Revenue: 54637000 Open source
20202020-12-31	Net margin	-77.1%	Net Income: -57403000 Open source Revenue: 74461000 Open source
20142014-12-31	Free cash flow margin	47.5%	Revenue: 55846000 Open source Operating Cash Flow: 27793000 Open source Capital Expenditure: 1285000 Open source
20152015-12-31	Free cash flow margin	-2,537%	Revenue: 1916000 Open source Operating Cash Flow: -47210000 Open source Capital Expenditure: 1399000 Open source
20162016-12-31	Free cash flow margin	-8,687.4%	Revenue: 572000 Open source Operating Cash Flow: -48068000 Open source Capital Expenditure: 1624000 Open source
20172017-12-31	Free cash flow margin	-11,923.8%	Revenue: 571000 Open source Operating Cash Flow: -66827000 Open source Capital Expenditure: 1258000 Open source
20182018-12-31	Free cash flow margin	-309.2%	Revenue: 34046000 Open source Operating Cash Flow: -104223000 Open source Capital Expenditure: 1064000 Open source
20192019-12-31	Free cash flow margin	-147.9%	Revenue: 54637000 Open source Operating Cash Flow: -80779000 Open source Capital Expenditure: 18000 Open source
20202020-12-31	Free cash flow margin	-68.1%	Revenue: 74461000 Open source Operating Cash Flow: -50708000 Open source Capital Expenditure: 0 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -50.7M 2020

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20142014-12-31	Operating cash flow	27793000	Operating Cash Flow: 27793000 Open source
20152015-12-31	Operating cash flow	-47210000	Operating Cash Flow: -47210000 Open source
20162016-12-31	Operating cash flow	-48068000	Operating Cash Flow: -48068000 Open source
20172017-12-31	Operating cash flow	-66827000	Operating Cash Flow: -66827000 Open source
20182018-12-31	Operating cash flow	-104223000	Operating Cash Flow: -104223000 Open source
20192019-12-31	Operating cash flow	-80779000	Operating Cash Flow: -80779000 Open source
20202020-12-31	Operating cash flow	-50708000	Operating Cash Flow: -50708000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -50.7M 2020

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20142014-12-31	Free cash flow	26508000	Operating Cash Flow: 27793000 Open source Capital Expenditure: 1285000 Open source
20152015-12-31	Free cash flow	-48609000	Operating Cash Flow: -47210000 Open source Capital Expenditure: 1399000 Open source
20162016-12-31	Free cash flow	-49692000	Operating Cash Flow: -48068000 Open source Capital Expenditure: 1624000 Open source
20172017-12-31	Free cash flow	-68085000	Operating Cash Flow: -66827000 Open source Capital Expenditure: 1258000 Open source
20182018-12-31	Free cash flow	-105287000	Operating Cash Flow: -104223000 Open source Capital Expenditure: 1064000 Open source
20192019-12-31	Free cash flow	-80797000	Operating Cash Flow: -80779000 Open source Capital Expenditure: 18000 Open source
20202020-12-31	Free cash flow	-50708000	Operating Cash Flow: -50708000 Open source Capital Expenditure: 0 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

141.6% 2020

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2014-12-31	Liabilities / assets	Not reported	No source recorded
20152015-12-31	Liabilities / assets	9.8%	Total Liabilities: 12556000 Open source Total Assets: 128743000 Open source
20162016-12-31	Liabilities / assets	7.2%	Total Liabilities: 10290000 Open source Total Assets: 142473000 Open source
20172017-12-31	Liabilities / assets	64.5%	Total Liabilities: 120050000 Open source Total Assets: 186176000 Open source
20182018-12-31	Liabilities / assets	61.7%	Total Liabilities: 144929000 Open source Total Assets: 234814000 Open source
20192019-12-31	Liabilities / assets	100.6%	Total Liabilities: 163051000 Open source Total Assets: 162158000 Open source
20202020-12-31	Liabilities / assets	141.6%	Total Liabilities: 170005000 Open source Total Assets: 120029000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

3.2× 2020

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2014-12-31	Current assets / current liabilities	Not reported	No source recorded
20152015-12-31	Current assets / current liabilities	9.59×	Current Assets: 113187000 Open source Current Liabilities: 11807000 Open source
20162016-12-31	Current assets / current liabilities	12.01×	Current Assets: 116987000 Open source Current Liabilities: 9743000 Open source
20172017-12-31	Current assets / current liabilities	10.79×	Current Assets: 179175000 Open source Current Liabilities: 16607000 Open source
20182018-12-31	Current assets / current liabilities	9.41×	Current Assets: 228373000 Open source Current Liabilities: 24276000 Open source
20192019-12-31	Current assets / current liabilities	5.58×	Current Assets: 150320000 Open source Current Liabilities: 26948000 Open source
20202020-12-31	Current assets / current liabilities	3.2×	Current Assets: 111736000 Open source Current Liabilities: 34867000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2014 2014-01-01 – 2014-12-31	USD 10.22 million Exact value Exact value: 10223000 USD 2014-01-01 – 2014-12-31: 10223000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Adamas Pharmaceuticals Inc · 2014-12-31 Adamas Pharmaceuticals Inc (edgar:1328143) Net Income: 10223000 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1328143/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: 10223000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000162828017001888/adms-20161231.xml#252176 Filing: 000162828017001888 The citation records this snapshot. The page link may show a newer release later.	USD 27.79 million Exact value Exact value: 27793000 USD 2014-01-01 – 2014-12-31: 27793000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Adamas Pharmaceuticals Inc · 2014-12-31 Adamas Pharmaceuticals Inc (edgar:1328143) Operating Cash Flow: 27793000 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1328143/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 27793000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000162828017001888/adms-20161231.xml#251541 Filing: 000162828017001888 The citation records this snapshot. The page link may show a newer release later.	USD 1.29 million Exact value Exact value: 1285000 USD 2014-01-01 – 2014-12-31: 1285000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Adamas Pharmaceuticals Inc · 2014-12-31 Adamas Pharmaceuticals Inc (edgar:1328143) Capital Expenditure: 1285000 USD Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1328143/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1285000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000162828017001888/adms-20161231.xml#267112 Filing: 000162828017001888 The citation records this snapshot. The page link may show a newer release later.	USD 26.51 million Calculation and evidence 27793000 − 1285000 USD Exact free cash flow: 26508000 USD 2014-01-01 – 2014-12-31: 27793000 USD · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 1285000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Adamas Pharmaceuticals Inc · 2014-12-31 Adamas Pharmaceuticals Inc (edgar:1328143) Free cash flow: 26508000 USD Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1328143?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 27793000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000162828017001888/adms-20161231.xml#251541 Filing: 000162828017001888 Input fundies:CapitalExpenditure: 1285000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000162828017001888/adms-20161231.xml#267112 Filing: 000162828017001888 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	−USD 51.8 million Exact value Exact value: -51802000 USD 2015-01-01 – 2015-12-31: -51802000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Adamas Pharmaceuticals Inc · 2015-12-31 Adamas Pharmaceuticals Inc (edgar:1328143) Net Income: -51802000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1328143/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -51802000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000162828018002045/adms-20171231.xml#251659 Filing: 000162828018002045 The citation records this snapshot. The page link may show a newer release later.	−USD 47.21 million Exact value Exact value: -47210000 USD 2015-01-01 – 2015-12-31: -47210000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Adamas Pharmaceuticals Inc · 2015-12-31 Adamas Pharmaceuticals Inc (edgar:1328143) Operating Cash Flow: -47210000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1328143/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -47210000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000162828018002045/adms-20171231.xml#251023 Filing: 000162828018002045 The citation records this snapshot. The page link may show a newer release later.	USD 1.4 million Exact value Exact value: 1399000 USD 2015-01-01 – 2015-12-31: 1399000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Adamas Pharmaceuticals Inc · 2015-12-31 Adamas Pharmaceuticals Inc (edgar:1328143) Capital Expenditure: 1399000 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1328143/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1399000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000162828018002045/adms-20171231.xml#264880 Filing: 000162828018002045 The citation records this snapshot. The page link may show a newer release later.	−USD 48.61 million Calculation and evidence -47210000 − 1399000 USD Exact free cash flow: -48609000 USD 2015-01-01 – 2015-12-31: -47210000 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 1399000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Adamas Pharmaceuticals Inc · 2015-12-31 Adamas Pharmaceuticals Inc (edgar:1328143) Free cash flow: -48609000 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1328143?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -47210000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000162828018002045/adms-20171231.xml#251023 Filing: 000162828018002045 Input fundies:CapitalExpenditure: 1399000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000162828018002045/adms-20171231.xml#264880 Filing: 000162828018002045 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−USD 60.06 million Exact value Exact value: -60058000 USD 2016-01-01 – 2016-12-31: -60058000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Adamas Pharmaceuticals Inc · 2016-12-31 Adamas Pharmaceuticals Inc (edgar:1328143) Net Income: -60058000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1328143/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -60058000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000132814319000011/adms-20181231.xml#272449 Filing: 000132814319000011 The citation records this snapshot. The page link may show a newer release later.	−USD 48.07 million Exact value Exact value: -48068000 USD 2016-01-01 – 2016-12-31: -48068000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Adamas Pharmaceuticals Inc · 2016-12-31 Adamas Pharmaceuticals Inc (edgar:1328143) Operating Cash Flow: -48068000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1328143/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -48068000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000132814319000011/adms-20181231.xml#271812 Filing: 000132814319000011 The citation records this snapshot. The page link may show a newer release later.	USD 1.62 million Exact value Exact value: 1624000 USD 2016-01-01 – 2016-12-31: 1624000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Adamas Pharmaceuticals Inc · 2016-12-31 Adamas Pharmaceuticals Inc (edgar:1328143) Capital Expenditure: 1624000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1328143/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1624000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000132814319000011/adms-20181231.xml#285059 Filing: 000132814319000011 The citation records this snapshot. The page link may show a newer release later.	−USD 49.69 million Calculation and evidence -48068000 − 1624000 USD Exact free cash flow: -49692000 USD 2016-01-01 – 2016-12-31: -48068000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 1624000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Adamas Pharmaceuticals Inc · 2016-12-31 Adamas Pharmaceuticals Inc (edgar:1328143) Free cash flow: -49692000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1328143?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -48068000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000132814319000011/adms-20181231.xml#271812 Filing: 000132814319000011 Input fundies:CapitalExpenditure: 1624000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000132814319000011/adms-20181231.xml#285059 Filing: 000132814319000011 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 89.49 million Exact value Exact value: -89490000 USD 2017-01-01 – 2017-12-31: -89490000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Adamas Pharmaceuticals Inc · 2017-12-31 Adamas Pharmaceuticals Inc (edgar:1328143) Net Income: -89490000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1328143/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -89490000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000132814320000012/adms-20191231.htm#2559715 Filing: 000132814320000012 The citation records this snapshot. The page link may show a newer release later.	−USD 66.83 million Exact value Exact value: -66827000 USD 2017-01-01 – 2017-12-31: -66827000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Adamas Pharmaceuticals Inc · 2017-12-31 Adamas Pharmaceuticals Inc (edgar:1328143) Operating Cash Flow: -66827000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1328143/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -66827000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000132814320000012/adms-20191231.htm#1420013 Filing: 000132814320000012 The citation records this snapshot. The page link may show a newer release later.	USD 1.26 million Exact value Exact value: 1258000 USD 2017-01-01 – 2017-12-31: 1258000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Adamas Pharmaceuticals Inc · 2017-12-31 Adamas Pharmaceuticals Inc (edgar:1328143) Capital Expenditure: 1258000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1328143/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1258000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000132814320000012/adms-20191231.htm#1425777 Filing: 000132814320000012 The citation records this snapshot. The page link may show a newer release later.	−USD 68.09 million Calculation and evidence -66827000 − 1258000 USD Exact free cash flow: -68085000 USD 2017-01-01 – 2017-12-31: -66827000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 1258000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Adamas Pharmaceuticals Inc · 2017-12-31 Adamas Pharmaceuticals Inc (edgar:1328143) Free cash flow: -68085000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1328143?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -66827000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000132814320000012/adms-20191231.htm#1420013 Filing: 000132814320000012 Input fundies:CapitalExpenditure: 1258000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000132814320000012/adms-20191231.htm#1425777 Filing: 000132814320000012 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 131 million Exact value Exact value: -130999000 USD 2018-01-01 – 2018-12-31: -130999000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Adamas Pharmaceuticals Inc · 2018-12-31 Adamas Pharmaceuticals Inc (edgar:1328143) Net Income: -130999000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1328143/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -130999000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000132814320000012/adms-20191231.htm#2558106 Filing: 000132814320000012 The citation records this snapshot. The page link may show a newer release later.	−USD 104.22 million Exact value Exact value: -104223000 USD 2018-01-01 – 2018-12-31: -104223000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Adamas Pharmaceuticals Inc · 2018-12-31 Adamas Pharmaceuticals Inc (edgar:1328143) Operating Cash Flow: -104223000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1328143/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -104223000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000132814320000012/adms-20191231.htm#1418648 Filing: 000132814320000012 The citation records this snapshot. The page link may show a newer release later.	USD 1.06 million Exact value Exact value: 1064000 USD 2018-01-01 – 2018-12-31: 1064000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Adamas Pharmaceuticals Inc · 2018-12-31 Adamas Pharmaceuticals Inc (edgar:1328143) Capital Expenditure: 1064000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1328143/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1064000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000132814320000012/adms-20191231.htm#1424481 Filing: 000132814320000012 The citation records this snapshot. The page link may show a newer release later.	−USD 105.29 million Calculation and evidence -104223000 − 1064000 USD Exact free cash flow: -105287000 USD 2018-01-01 – 2018-12-31: -104223000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 1064000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Adamas Pharmaceuticals Inc · 2018-12-31 Adamas Pharmaceuticals Inc (edgar:1328143) Free cash flow: -105287000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1328143?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -104223000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000132814320000012/adms-20191231.htm#1418648 Filing: 000132814320000012 Input fundies:CapitalExpenditure: 1064000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000132814320000012/adms-20191231.htm#1424481 Filing: 000132814320000012 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 105.19 million Exact value Exact value: -105186000 USD 2019-01-01 – 2019-12-31: -105186000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Adamas Pharmaceuticals Inc · 2019-12-31 Adamas Pharmaceuticals Inc (edgar:1328143) Net Income: -105186000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1328143/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -105186000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000132814321000019/adms-20201231.htm#1775175 Filing: 000132814321000019 The citation records this snapshot. The page link may show a newer release later.	−USD 80.78 million Exact value Exact value: -80779000 USD 2019-01-01 – 2019-12-31: -80779000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Adamas Pharmaceuticals Inc · 2019-12-31 Adamas Pharmaceuticals Inc (edgar:1328143) Operating Cash Flow: -80779000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1328143/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -80779000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000132814321000019/adms-20201231.htm#982773 Filing: 000132814321000019 The citation records this snapshot. The page link may show a newer release later.	USD 18,000 Exact value Exact value: 18000 USD 2019-01-01 – 2019-12-31: 18000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Adamas Pharmaceuticals Inc · 2019-12-31 Adamas Pharmaceuticals Inc (edgar:1328143) Capital Expenditure: 18000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1328143/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 18000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000132814321000019/adms-20201231.htm#986032 Filing: 000132814321000019 The citation records this snapshot. The page link may show a newer release later.	−USD 80.8 million Calculation and evidence -80779000 − 18000 USD Exact free cash flow: -80797000 USD 2019-01-01 – 2019-12-31: -80779000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 18000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Adamas Pharmaceuticals Inc · 2019-12-31 Adamas Pharmaceuticals Inc (edgar:1328143) Free cash flow: -80797000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1328143?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -80779000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000132814321000019/adms-20201231.htm#982773 Filing: 000132814321000019 Input fundies:CapitalExpenditure: 18000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000132814321000019/adms-20201231.htm#986032 Filing: 000132814321000019 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 57.4 million Exact value Exact value: -57403000 USD 2020-01-01 – 2020-12-31: -57403000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Adamas Pharmaceuticals Inc · 2020-12-31 Adamas Pharmaceuticals Inc (edgar:1328143) Net Income: -57403000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1328143/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -57403000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000132814321000019/adms-20201231.htm#1773928 Filing: 000132814321000019 The citation records this snapshot. The page link may show a newer release later.	−USD 50.71 million Exact value Exact value: -50708000 USD 2020-01-01 – 2020-12-31: -50708000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Adamas Pharmaceuticals Inc · 2020-12-31 Adamas Pharmaceuticals Inc (edgar:1328143) Operating Cash Flow: -50708000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1328143/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -50708000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000132814321000019/adms-20201231.htm#981723 Filing: 000132814321000019 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2020-01-01 – 2020-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Adamas Pharmaceuticals Inc · 2020-12-31 Adamas Pharmaceuticals Inc (edgar:1328143) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1328143/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000132814321000019/adms-20201231.htm#985048 Filing: 000132814321000019 The citation records this snapshot. The page link may show a newer release later.	−USD 50.71 million Calculation and evidence -50708000 − 0 USD Exact free cash flow: -50708000 USD 2020-01-01 – 2020-12-31: -50708000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Adamas Pharmaceuticals Inc · 2020-12-31 Adamas Pharmaceuticals Inc (edgar:1328143) Free cash flow: -50708000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1328143?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -50708000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000132814321000019/adms-20201231.htm#981723 Filing: 000132814321000019 Input fundies:CapitalExpenditure: 0 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1328143/000132814321000019/adms-20201231.htm#985048 Filing: 000132814321000019 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

150 filings · 2,853 latest values · 2,853 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001328143, 1328143, ADMS, edgar:1328143

Also known as Adamas Pharmaceuticals Inc, NeuroMolecular Pharmaceuticals Inc

Adamas Pharmaceuticals Inc

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2020 2020-01-01 – 2020-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation